Financhill
Sell
29

EVAX Quote, Financials, Valuation and Earnings

Last price:
$1.90
Seasonality move :
-2.36%
Day range:
$1.80 - $1.93
52-week range:
$1.70 - $22.05
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.49x
P/B ratio:
150.74x
Volume:
44.7K
Avg. volume:
2.5M
1-year change:
-87.93%
Market cap:
$11.2M
Revenue:
$73K
EPS (TTM):
-$2.80

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
EVAX
Evaxion Biotech AS
$1.7M -$0.15 6174.51% -98% $13.25
ADAP
Adaptimmune Therapeutics PLC
$8.4M -$0.15 4199.24% -9.44% $2.30
ASND
Ascendis Pharma AS
$123.2M -$0.96 -2.6% -34.91% $211.37
CLLS
Cellectis SA
$9.6M -$0.21 3346.52% -69.12% $5.80
DBVT
DBV Technologies SA
$1.1M -$0.22 -- -59.89% $21.81
NVO
Novo Nordisk AS
$11.5B $0.80 22.5% 10.09% $112.90
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
EVAX
Evaxion Biotech AS
$1.78 $13.25 $11.2M -- $0.00 0% 0.49x
ADAP
Adaptimmune Therapeutics PLC
$0.46 $2.30 $116.9M -- $0.00 0% 0.64x
ASND
Ascendis Pharma AS
$168.84 $211.37 $10.1B -- $0.00 0% 24.94x
CLLS
Cellectis SA
$1.24 $5.80 $124.1M -- $0.00 0% 3.82x
DBVT
DBV Technologies SA
$4.87 $21.81 $99.9M -- $0.00 0% --
NVO
Novo Nordisk AS
$77.15 $112.90 $342.5B 23.50x $0.52 1.88% 8.18x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
EVAX
Evaxion Biotech AS
-- -2.040 -- 2.80x
ADAP
Adaptimmune Therapeutics PLC
38.4% 2.439 20.51% 3.54x
ASND
Ascendis Pharma AS
114.08% 0.763 10.82% 0.81x
CLLS
Cellectis SA
26.36% 1.831 21.83% 1.74x
DBVT
DBV Technologies SA
-- -0.036 -- --
NVO
Novo Nordisk AS
40.09% 0.871 3.51% 0.52x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
EVAX
Evaxion Biotech AS
-- -$1.7M -238.97% -- -54.59% --
ADAP
Adaptimmune Therapeutics PLC
-- -$14.7M -55.22% -67.8% -38.33% -$54.9M
ASND
Ascendis Pharma AS
$170.4M $408.3K -69.61% -880.05% -24.36% -$90.9M
CLLS
Cellectis SA
-- -$10.8M -57.78% -79.78% -130.83% -$6.6M
DBVT
DBV Technologies SA
-- -$30.3M -- -- -- -$22.9M
NVO
Novo Nordisk AS
$10.4B $5.2B 60.28% 86.85% 40.78% -$786.4M

Evaxion Biotech AS vs. Competitors

  • Which has Higher Returns EVAX or ADAP?

    Adaptimmune Therapeutics PLC has a net margin of -64.14% compared to Evaxion Biotech AS's net margin of -43.07%. Evaxion Biotech AS's return on equity of -- beat Adaptimmune Therapeutics PLC's return on equity of -67.8%.

    Company Gross Margin Earnings Per Share Invested Capital
    EVAX
    Evaxion Biotech AS
    -- -$0.40 $74K
    ADAP
    Adaptimmune Therapeutics PLC
    -- -$0.06 $129.9M
  • What do Analysts Say About EVAX or ADAP?

    Evaxion Biotech AS has a consensus price target of $13.25, signalling upside risk potential of 644.38%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $2.30 which suggests that it could grow by 403.61%. Given that Evaxion Biotech AS has higher upside potential than Adaptimmune Therapeutics PLC, analysts believe Evaxion Biotech AS is more attractive than Adaptimmune Therapeutics PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    EVAX
    Evaxion Biotech AS
    1 0 0
    ADAP
    Adaptimmune Therapeutics PLC
    3 2 0
  • Is EVAX or ADAP More Risky?

    Evaxion Biotech AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.520, suggesting its more volatile than the S&P 500 by 152.023%.

  • Which is a Better Dividend Stock EVAX or ADAP?

    Evaxion Biotech AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evaxion Biotech AS pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EVAX or ADAP?

    Evaxion Biotech AS quarterly revenues are $3M, which are smaller than Adaptimmune Therapeutics PLC quarterly revenues of $40.9M. Evaxion Biotech AS's net income of -$1.9M is higher than Adaptimmune Therapeutics PLC's net income of -$17.6M. Notably, Evaxion Biotech AS's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion Biotech AS is 0.49x versus 0.64x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EVAX
    Evaxion Biotech AS
    0.49x -- $3M -$1.9M
    ADAP
    Adaptimmune Therapeutics PLC
    0.64x -- $40.9M -$17.6M
  • Which has Higher Returns EVAX or ASND?

    Ascendis Pharma AS has a net margin of -64.14% compared to Evaxion Biotech AS's net margin of -22.12%. Evaxion Biotech AS's return on equity of -- beat Ascendis Pharma AS's return on equity of -880.05%.

    Company Gross Margin Earnings Per Share Invested Capital
    EVAX
    Evaxion Biotech AS
    -- -$0.40 $74K
    ASND
    Ascendis Pharma AS
    91.94% -$0.68 $781.4M
  • What do Analysts Say About EVAX or ASND?

    Evaxion Biotech AS has a consensus price target of $13.25, signalling upside risk potential of 644.38%. On the other hand Ascendis Pharma AS has an analysts' consensus of $211.37 which suggests that it could grow by 25.19%. Given that Evaxion Biotech AS has higher upside potential than Ascendis Pharma AS, analysts believe Evaxion Biotech AS is more attractive than Ascendis Pharma AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    EVAX
    Evaxion Biotech AS
    1 0 0
    ASND
    Ascendis Pharma AS
    12 1 0
  • Is EVAX or ASND More Risky?

    Evaxion Biotech AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ascendis Pharma AS has a beta of 0.616, suggesting its less volatile than the S&P 500 by 38.413%.

  • Which is a Better Dividend Stock EVAX or ASND?

    Evaxion Biotech AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ascendis Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evaxion Biotech AS pays -- of its earnings as a dividend. Ascendis Pharma AS pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EVAX or ASND?

    Evaxion Biotech AS quarterly revenues are $3M, which are smaller than Ascendis Pharma AS quarterly revenues of $185.4M. Evaxion Biotech AS's net income of -$1.9M is higher than Ascendis Pharma AS's net income of -$41M. Notably, Evaxion Biotech AS's price-to-earnings ratio is -- while Ascendis Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion Biotech AS is 0.49x versus 24.94x for Ascendis Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EVAX
    Evaxion Biotech AS
    0.49x -- $3M -$1.9M
    ASND
    Ascendis Pharma AS
    24.94x -- $185.4M -$41M
  • Which has Higher Returns EVAX or CLLS?

    Cellectis SA has a net margin of -64.14% compared to Evaxion Biotech AS's net margin of -142.32%. Evaxion Biotech AS's return on equity of -- beat Cellectis SA's return on equity of -79.78%.

    Company Gross Margin Earnings Per Share Invested Capital
    EVAX
    Evaxion Biotech AS
    -- -$0.40 $74K
    CLLS
    Cellectis SA
    -- -$0.23 $175.7M
  • What do Analysts Say About EVAX or CLLS?

    Evaxion Biotech AS has a consensus price target of $13.25, signalling upside risk potential of 644.38%. On the other hand Cellectis SA has an analysts' consensus of $5.80 which suggests that it could grow by 367.74%. Given that Evaxion Biotech AS has higher upside potential than Cellectis SA, analysts believe Evaxion Biotech AS is more attractive than Cellectis SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    EVAX
    Evaxion Biotech AS
    1 0 0
    CLLS
    Cellectis SA
    2 1 0
  • Is EVAX or CLLS More Risky?

    Evaxion Biotech AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cellectis SA has a beta of 3.275, suggesting its more volatile than the S&P 500 by 227.454%.

  • Which is a Better Dividend Stock EVAX or CLLS?

    Evaxion Biotech AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evaxion Biotech AS pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EVAX or CLLS?

    Evaxion Biotech AS quarterly revenues are $3M, which are smaller than Cellectis SA quarterly revenues of $16.2M. Evaxion Biotech AS's net income of -$1.9M is higher than Cellectis SA's net income of -$23.1M. Notably, Evaxion Biotech AS's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion Biotech AS is 0.49x versus 3.82x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EVAX
    Evaxion Biotech AS
    0.49x -- $3M -$1.9M
    CLLS
    Cellectis SA
    3.82x -- $16.2M -$23.1M
  • Which has Higher Returns EVAX or DBVT?

    DBV Technologies SA has a net margin of -64.14% compared to Evaxion Biotech AS's net margin of --. Evaxion Biotech AS's return on equity of -- beat DBV Technologies SA's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    EVAX
    Evaxion Biotech AS
    -- -$0.40 $74K
    DBVT
    DBV Technologies SA
    -- -$1.60 --
  • What do Analysts Say About EVAX or DBVT?

    Evaxion Biotech AS has a consensus price target of $13.25, signalling upside risk potential of 644.38%. On the other hand DBV Technologies SA has an analysts' consensus of $21.81 which suggests that it could grow by 347.91%. Given that Evaxion Biotech AS has higher upside potential than DBV Technologies SA, analysts believe Evaxion Biotech AS is more attractive than DBV Technologies SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    EVAX
    Evaxion Biotech AS
    1 0 0
    DBVT
    DBV Technologies SA
    0 0 0
  • Is EVAX or DBVT More Risky?

    Evaxion Biotech AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of 0.707, suggesting its less volatile than the S&P 500 by 29.271%.

  • Which is a Better Dividend Stock EVAX or DBVT?

    Evaxion Biotech AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evaxion Biotech AS pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EVAX or DBVT?

    Evaxion Biotech AS quarterly revenues are $3M, which are larger than DBV Technologies SA quarterly revenues of --. Evaxion Biotech AS's net income of -$1.9M is higher than DBV Technologies SA's net income of -$30.4M. Notably, Evaxion Biotech AS's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion Biotech AS is 0.49x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EVAX
    Evaxion Biotech AS
    0.49x -- $3M -$1.9M
    DBVT
    DBV Technologies SA
    -- -- -- -$30.4M
  • Which has Higher Returns EVAX or NVO?

    Novo Nordisk AS has a net margin of -64.14% compared to Evaxion Biotech AS's net margin of 32.95%. Evaxion Biotech AS's return on equity of -- beat Novo Nordisk AS's return on equity of 86.85%.

    Company Gross Margin Earnings Per Share Invested Capital
    EVAX
    Evaxion Biotech AS
    -- -$0.40 $74K
    NVO
    Novo Nordisk AS
    84.8% $0.91 $33.4B
  • What do Analysts Say About EVAX or NVO?

    Evaxion Biotech AS has a consensus price target of $13.25, signalling upside risk potential of 644.38%. On the other hand Novo Nordisk AS has an analysts' consensus of $112.90 which suggests that it could grow by 48.19%. Given that Evaxion Biotech AS has higher upside potential than Novo Nordisk AS, analysts believe Evaxion Biotech AS is more attractive than Novo Nordisk AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    EVAX
    Evaxion Biotech AS
    1 0 0
    NVO
    Novo Nordisk AS
    4 4 1
  • Is EVAX or NVO More Risky?

    Evaxion Biotech AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.420, suggesting its less volatile than the S&P 500 by 58.038%.

  • Which is a Better Dividend Stock EVAX or NVO?

    Evaxion Biotech AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 1.88% to investors and pays a quarterly dividend of $0.52 per share. Evaxion Biotech AS pays -- of its earnings as a dividend. Novo Nordisk AS pays out 43.71% of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios EVAX or NVO?

    Evaxion Biotech AS quarterly revenues are $3M, which are smaller than Novo Nordisk AS quarterly revenues of $12.2B. Evaxion Biotech AS's net income of -$1.9M is lower than Novo Nordisk AS's net income of $4B. Notably, Evaxion Biotech AS's price-to-earnings ratio is -- while Novo Nordisk AS's PE ratio is 23.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion Biotech AS is 0.49x versus 8.18x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EVAX
    Evaxion Biotech AS
    0.49x -- $3M -$1.9M
    NVO
    Novo Nordisk AS
    8.18x 23.50x $12.2B $4B

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Is Ford Stock Undervalued Amid the EV Transition?
Is Ford Stock Undervalued Amid the EV Transition?

There is a lot going on in the electric vehicle…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Sell
49
SMTC alert for Mar 17

Semtech [SMTC] is down 0.49% over the past day.

Buy
62
PLPC alert for Mar 17

Preformed Line Products [PLPC] is up 3.8% over the past day.

Sell
50
NUTX alert for Mar 17

Nutex Health [NUTX] is up 4.82% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock